TABLE 3.

Concentrations of arachidonate 5-lipoxygenase pathway metabolites and IL-6 detected in AF of patients groups described in Table 1

Group	5-HETE	5-OxoETE	LTB4	5(S),12(S)-diHETE	LXB4	IL-6
TLB (n = 35)	11.6 (7.10–25.4) [35]	0.02 (0.02–0.02) [5]	0.02 (0.02–3.35) [17]	6.84 (4.92–11.4) [35]	0.02 (0.02–1.97) [15]	1.08 (0.83–1.57) [11]
TCC-NI (n = 4)	6.19 (5.43–7.80) [4]	0.02 (0.02–0.02) [0]	0.02 (0.02–0.02) [0]	4.22 (3.96–5.13) [4]	0.02 (0.02–0.02) [0]	1.48 (0.97–2.00) [4]
TCC-SI (n = 8)	13.9 (5.37–21.6) [8]	0.02 (0.02–0.02) [1]	0.02 (0.02–2.47) [3]	6.17 (2.93–7.72) [8]	0.02 (0.02–1.54) [3]	10.7 (3.22–16.0) [8]
TCC-IAI-MIAC (n = 12)	41.4 (16.0–55.4) [12]	0.02 (0.02–1.68) [4]	4.93 (3.91–10.2) [12]	8.85 (7.58–15.2) [12]	1.50 (0.02–2.58) [7]	13.95 (5.02–22.01) [12]
SCX (n = 28)	0.11 (0.07–0.15) [27]	0.02 (0.02–0.02) [0]	0.26 (0.16–0.35) [28]	0.93 (0.58–1.36) [28]	0.02 (0.02–0.02) [0]	ND
PTL-IAI-noMIAC (n = 15)	2.55 (1.31–8.21) [12]	0.02 (0.02–0.02) [0]	0.02 (0.02–0.02) [1]	2.16 (0.02–3.78) [8]	0.02 (0.02–0.02) [1]	8.39 (4.55–22.3) [15]
PLT-IAI-MIAC (n = 10)	12.8 (6.21 – 53.7) [10]	0.02 (0.02 – 0.02) [2]	3.19 (0.02 – 7.22) [6]	4.61 (2.92 – 6.39) [8]	0.02 (0.02 – 3.20) [3]	96.0 (49.3 – 193.8) [10]
IAI-noMIAC (n = 27)a	5.92 (2.25–12.9) [24]	0.02 (0.02–0.02) [1]	0.02 (0.02–0.02) [4]	3.69 (1.06–5.07) [20]	0.02 (0.02–0.02) [4]	5.98 (3.03–18.2) [27]
IAI-MIAC (n = 22)b	38.4 (8.2–54.8) [22]	0.02 (0.02–0.83) [6]	4.49 (3.14–7.96) [18]	7.57 (4.72–11.7) [20]	0.02 (0.02–2.62) [10]	27.1 (12.7–80.9) [22]

Median and interquartile range (in parentheses) data are presented in nanomolar concentration for lipids and nanograms/milliliter for IL-6. Values in brackets denote the number of samples with detectable levels. ND, not determined.

^aCumulative data from TCC-NI, TCC-SI, and PTL-IAI-noMIAC samples.

^bCumulative data from TCC-IAI-MIAC and PTL-IAI-MIAC samples.